Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
Comparative Analysis of National Drug Policies - Second Workshop Geneva, 10-13 June 1996 - EDM Research Series No. 025
(1997; 175 pages) View the PDF document
Table of Contents
View the documentExecutive summary
View the documentI. Introduction
Open this folder and view contentsII. Background on the research project
Open this folder and view contentsIII. Second workshop
Open this folder and view contentsIV. Preliminary findings
Open this folder and view contentsV. Conclusions of the workshop and follow-up plans
Open this folder and view contentsAnnex 1: Research proposal
View the documentAnnex 2: List of participants
View the documentAnnex 3: Agenda
View the documentAnnex 4: Questionnaire on NDP performance assessment
Open this folder and view contentsAnnex 5: Achievements of the national drug policies in the 12 countries
View the documentAnnex 6: Consolidated tables
View the documentOther documents in the DAP Research Series
 

Annex 4: Questionnaire on NDP performance assessment

Second workshop on the research on the comparative analysis of NDP

1. The relevance of the method to assess your country's policy

1. Were you able through the use of the indicators to evaluate the outcomes of your NDP?

_______________________________________________________
_______________________________________________________
_______________________________________________________
_______________________________________________________
_______________________________________________________

2. Were you able through the use of the indicators to assess the implementation of the NDP?

_______________________________________________________
_______________________________________________________
_______________________________________________________
_______________________________________________________
_______________________________________________________

3. Did you find things you did not know about the NDP from the indicators?

_______________________________________________________
_______________________________________________________
_______________________________________________________
_______________________________________________________
_______________________________________________________

4. Which aspects of the NDP were not covered by the indicators?

_______________________________________________________
_______________________________________________________
_______________________________________________________
_______________________________________________________
_______________________________________________________

2. The findings:

Based on the data collected (ST, PR, OT indicators), there are at least four questions:

Please circle the correct number.
1 = does not work
5 = works very well











1. Has the policy achieved the objectives of:























• Availability of essential drugs?


1


2


3


4


5














• Accessibility to essential drugs?


1


2


3


4


5














• Quality of drugs?


1


2


3


4


5














• Rational use of drugs?


1


2


3


4


5

2. Which components of the policy work and which ones do not work (policy structures and processes)?

Please circle the correct number.
1 = does not work
5 = works very well











(a) Legislation and regulation


1


2


3


4


5












(b) Essential drugs selection and drug registration


1


2


3


4


5












(c) Drug allocation in the health budget/public sector financing policy


1


2


3


4


5












(d) Public sector procurement procedures


1


2


3


4


5












(e) Public sector distribution and logistics


1


2


3


4


5












(f) Pricing policy


1


2


3


4


5












(g) Information and continuing education on drug use


1


2


3


4


5

Comments, if needed:

___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________
___________________________________________________

3. What is your assessment of the strengths of the national drug policy?

_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________

4. What is your assessment of the weaknesses of the national drug policy?

_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________

3. The analysis and interpretations of the findings


Yes


No

 


1. Are there components (a, b, c, d, e,...) which have received more attention and were implemented first? If yes, can you identify the reasons for this?


_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________

2. Were there components (a, b, c, d, e,...) that were easy to implement and components that were difficult to implement? If yes, can you identify which ones and why?


_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________

3. Are there components (a, b, c, d, e,...) which seem to have been more important for achieving the NDP objectives than others? If yes, can you explain why?


_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________

4. Were there any linkages in performance across components, so that if one component was performing well, other also performed well? If yes, can you comment upon?


_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________
_________________________________________________________________

 

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: March 20, 2014